BCNU en es it fr

BCNU Brand names, BCNU Analogs

BCNU Brand Names Mixture

  • No information avaliable

BCNU Chemical_Formula


BCNU RX_link

BCNU fda sheet

BCNU msds (material safety sheet)


BCNU Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

BCNU Molecular Weight

214.049 g/mol

BCNU Melting Point

31 oC

BCNU H2O Solubility

< 0.1 g/100 mL at 18 °C

BCNU State




BCNU Dosage Forms

Powder for solution; Wafer

BCNU Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

BCNU Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

BCNU Absorption

5 to 28% bioavailability

BCNU side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

BCNU Patient Information

No information avaliable

BCNU Organisms Affected

Humans and other mammals